10. OPERATING LEASE RIGHT-OF-USE ASSETS AND LEASE OBLIGATIONS

The Company has one operating lease primarily for office and administration.

During December 2021, the Company entered into a new lease agreement. The Company paid an $85,000 deposit that would be returned at the end of the lease. In December 2022, the Company started a new lease with an additional suite in the same premise as the existing lease.

The Company’s existing operating lease is nearing the end of its contractual term. As of June 30, 2026, the Company was in negotiations for a new lease arrangement for its office and administrative facilities. The terms of the proposed lease have not been finalized, and no definitive lease agreement has been executed. Accordingly, no right-of-use asset or lease liability related to a new lease arrangement has been recognized as of June 30, 2026.

When measuring the lease obligations, the Company discounted lease payments using its incremental borrowing rate. The weighted-average-rate applied is 11.4%.

 SCHEDULE OF OPERATING LEASE OBLIGATIONS

BIOTRICITY INC.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

JUNE 30, 2026 (Unaudited)

(Expressed in US dollars)

The operating lease expense was $141,554 for the three months ended June 30, 2026 (2025: $159,702) and included in the selling, general and administrative expenses. Operating cash flows from operating leases amounted to $154,189 and $149,698 during the three months ended June 30, 2026, and June 30, 2025, respectively.

The following table represents the contractual undiscounted cash flows for lease obligations as at June 30, 2026:

 SCHEDULE OF CONTRACTUAL UNDISCOUNTED CASH FLOWS FOR LEASE OBLIGATION